Bioventix (GB:BVXP) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Bioventix PLC has released its Annual Report for the year ending June 2024 and announced its upcoming Annual General Meeting on December 5th. The company, known for its high-affinity monoclonal antibodies used in clinical diagnostics, continues to supply a wide range of antibodies to multinational diagnostics firms. Investors can access these documents through the company’s website to stay informed about its financial performance and strategic direction.
For further insights into GB:BVXP stock, check out TipRanks’ Stock Analysis page.
